View in EDS PDF Full Text

The Cost Effectiveness of Nalmefene for Reduction of Alcohol Consumption in Alcohol-Dependent Patients with High or Very High Drinking-Risk Levels from a UK Societal Perspective.

Saved in:
Bibliographic Details
Title: The Cost Effectiveness of Nalmefene for Reduction of Alcohol Consumption in Alcohol-Dependent Patients with High or Very High Drinking-Risk Levels from a UK Societal Perspective.
Authors: Brodtkorb, Thor-Henrik, Bell, Melissa, Irving, Adam, Laramée, Philippe, Irving, Adam H (AUTHOR)
Source: CNS Drugs. Feb2016, Vol. 30 Issue 2, p163-177. 15p.
Subjects: Alcoholism treatment, Prevention of alcoholism, People with alcoholism, Cost effectiveness, Medical care costs, Medical economics, Alcoholism, Economic impact of crime, Medical care cost statistics, Combined modality therapy, Comparative studies, Crime, Economic aspects of diseases, Alcohol drinking, Labor productivity, Research methodology, Medical cooperation, Naltrexone, Probability theory, Psychotherapy, Research, Evaluation research, Relative medical risk, Alcohol deterrents, Patients' attitudes, Statistical models, Economics, Therapeutics
Geographic Terms: United Kingdom
Abstract: Aim: To evaluate costs and health outcomes of nalmefene plus psychosocial support, compared with psychosocial intervention alone, for reducing alcohol consumption in alcohol-dependent patients, specifically focusing on societal costs related to productivity losses and crime.Methods: A Markov model was constructed to model costs and health outcomes of the treatments over 5 years. Analyses were conducted for nalmefene's licensed population: adults with both alcohol dependence and high or very high drinking-risk levels (DRLs) who do not require immediate detoxification and who have high or very high DRLs after initial assessment. The main outcome measure was cost per quality-adjusted life-year (QALY) gained as assessed from a UK societal perspective. Alcohol-attributable productivity loss, crime and health events occurring at different levels of alcohol consumption were taken from published risk-relation studies. Health-related and societal costs were drawn from public data and the literature. Data on the treatment effect, as well as baseline characteristics of the modelled population and utilities, came from three pivotal phase 3 trials of nalmefene.Results: Nalmefene plus psychosocial support was dominant compared with psychosocial intervention alone, resulting in QALYs gained and reduced societal costs. Sensitivity analyses showed that this conclusion was robust. Nalmefene plus psychosocial support led to per-patient reduced costs of £3324 and £2483, due to reduced productivity losses and crime events, respectively.Conclusion: Nalmefene is cost effective from a UK societal perspective, resulting in greater QALY gains and lower costs compared with psychosocial support alone. Nalmefene demonstrates considerable public benefits by reducing alcohol-attributable productivity losses and crime events in adults with both alcohol dependence and high or very high DRLs who do not require immediate detoxification and who have high or very high DRLs after initial assessment. [ABSTRACT FROM AUTHOR]
Copyright of CNS Drugs is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 113545569
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: The Cost Effectiveness of Nalmefene for Reduction of Alcohol Consumption in Alcohol-Dependent Patients with High or Very High Drinking-Risk Levels from a UK Societal Perspective.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Brodtkorb%2C+Thor-Henrik%22">Brodtkorb, Thor-Henrik</searchLink><br /><searchLink fieldCode="AR" term="%22Bell%2C+Melissa%22">Bell, Melissa</searchLink><br /><searchLink fieldCode="AR" term="%22Irving%2C+Adam%22">Irving, Adam</searchLink><br /><searchLink fieldCode="AR" term="%22Laramée%2C+Philippe%22">Laramée, Philippe</searchLink><br /><searchLink fieldCode="AR" term="%22Irving%2C+Adam+H%22">Irving, Adam H</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22CNS+Drugs%22">CNS Drugs</searchLink>. Feb2016, Vol. 30 Issue 2, p163-177. 15p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Alcoholism+treatment%22">Alcoholism treatment</searchLink><br /><searchLink fieldCode="DE" term="%22Prevention+of+alcoholism%22">Prevention of alcoholism</searchLink><br /><searchLink fieldCode="DE" term="%22People+with+alcoholism%22">People with alcoholism</searchLink><br /><searchLink fieldCode="DE" term="%22Cost+effectiveness%22">Cost effectiveness</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+care+costs%22">Medical care costs</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+economics%22">Medical economics</searchLink><br /><searchLink fieldCode="DE" term="%22Alcoholism%22">Alcoholism</searchLink><br /><searchLink fieldCode="DE" term="%22Economic+impact+of+crime%22">Economic impact of crime</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+care+cost+statistics%22">Medical care cost statistics</searchLink><br /><searchLink fieldCode="DE" term="%22Combined+modality+therapy%22">Combined modality therapy</searchLink><br /><searchLink fieldCode="DE" term="%22Comparative+studies%22">Comparative studies</searchLink><br /><searchLink fieldCode="DE" term="%22Crime%22">Crime</searchLink><br /><searchLink fieldCode="DE" term="%22Economic+aspects+of+diseases%22">Economic aspects of diseases</searchLink><br /><searchLink fieldCode="DE" term="%22Alcohol+drinking%22">Alcohol drinking</searchLink><br /><searchLink fieldCode="DE" term="%22Labor+productivity%22">Labor productivity</searchLink><br /><searchLink fieldCode="DE" term="%22Research+methodology%22">Research methodology</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+cooperation%22">Medical cooperation</searchLink><br /><searchLink fieldCode="DE" term="%22Naltrexone%22">Naltrexone</searchLink><br /><searchLink fieldCode="DE" term="%22Probability+theory%22">Probability theory</searchLink><br /><searchLink fieldCode="DE" term="%22Psychotherapy%22">Psychotherapy</searchLink><br /><searchLink fieldCode="DE" term="%22Research%22">Research</searchLink><br /><searchLink fieldCode="DE" term="%22Evaluation+research%22">Evaluation research</searchLink><br /><searchLink fieldCode="DE" term="%22Relative+medical+risk%22">Relative medical risk</searchLink><br /><searchLink fieldCode="DE" term="%22Alcohol+deterrents%22">Alcohol deterrents</searchLink><br /><searchLink fieldCode="DE" term="%22Patients'+attitudes%22">Patients' attitudes</searchLink><br /><searchLink fieldCode="DE" term="%22Statistical+models%22">Statistical models</searchLink><br /><searchLink fieldCode="DE" term="%22Economics%22">Economics</searchLink><br /><searchLink fieldCode="DE" term="%22Therapeutics%22">Therapeutics</searchLink>
– Name: SubjectGeographic
  Label: Geographic Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22United+Kingdom%22">United Kingdom</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: <bold>Aim: </bold>To evaluate costs and health outcomes of nalmefene plus psychosocial support, compared with psychosocial intervention alone, for reducing alcohol consumption in alcohol-dependent patients, specifically focusing on societal costs related to productivity losses and crime.<bold>Methods: </bold>A Markov model was constructed to model costs and health outcomes of the treatments over 5 years. Analyses were conducted for nalmefene's licensed population: adults with both alcohol dependence and high or very high drinking-risk levels (DRLs) who do not require immediate detoxification and who have high or very high DRLs after initial assessment. The main outcome measure was cost per quality-adjusted life-year (QALY) gained as assessed from a UK societal perspective. Alcohol-attributable productivity loss, crime and health events occurring at different levels of alcohol consumption were taken from published risk-relation studies. Health-related and societal costs were drawn from public data and the literature. Data on the treatment effect, as well as baseline characteristics of the modelled population and utilities, came from three pivotal phase 3 trials of nalmefene.<bold>Results: </bold>Nalmefene plus psychosocial support was dominant compared with psychosocial intervention alone, resulting in QALYs gained and reduced societal costs. Sensitivity analyses showed that this conclusion was robust. Nalmefene plus psychosocial support led to per-patient reduced costs of £3324 and £2483, due to reduced productivity losses and crime events, respectively.<bold>Conclusion: </bold>Nalmefene is cost effective from a UK societal perspective, resulting in greater QALY gains and lower costs compared with psychosocial support alone. Nalmefene demonstrates considerable public benefits by reducing alcohol-attributable productivity losses and crime events in adults with both alcohol dependence and high or very high DRLs who do not require immediate detoxification and who have high or very high DRLs after initial assessment. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of CNS Drugs is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=113545569
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s40263-016-0310-2
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 15
        StartPage: 163
    Subjects:
      – SubjectFull: Alcoholism treatment
        Type: general
      – SubjectFull: Prevention of alcoholism
        Type: general
      – SubjectFull: People with alcoholism
        Type: general
      – SubjectFull: Cost effectiveness
        Type: general
      – SubjectFull: Medical care costs
        Type: general
      – SubjectFull: Medical economics
        Type: general
      – SubjectFull: Alcoholism
        Type: general
      – SubjectFull: Economic impact of crime
        Type: general
      – SubjectFull: Medical care cost statistics
        Type: general
      – SubjectFull: Combined modality therapy
        Type: general
      – SubjectFull: Comparative studies
        Type: general
      – SubjectFull: Crime
        Type: general
      – SubjectFull: Economic aspects of diseases
        Type: general
      – SubjectFull: Alcohol drinking
        Type: general
      – SubjectFull: Labor productivity
        Type: general
      – SubjectFull: Research methodology
        Type: general
      – SubjectFull: Medical cooperation
        Type: general
      – SubjectFull: Naltrexone
        Type: general
      – SubjectFull: Probability theory
        Type: general
      – SubjectFull: Psychotherapy
        Type: general
      – SubjectFull: Research
        Type: general
      – SubjectFull: Evaluation research
        Type: general
      – SubjectFull: Relative medical risk
        Type: general
      – SubjectFull: Alcohol deterrents
        Type: general
      – SubjectFull: Patients' attitudes
        Type: general
      – SubjectFull: Statistical models
        Type: general
      – SubjectFull: Economics
        Type: general
      – SubjectFull: Therapeutics
        Type: general
      – SubjectFull: United Kingdom
        Type: general
    Titles:
      – TitleFull: The Cost Effectiveness of Nalmefene for Reduction of Alcohol Consumption in Alcohol-Dependent Patients with High or Very High Drinking-Risk Levels from a UK Societal Perspective.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Brodtkorb, Thor-Henrik
      – PersonEntity:
          Name:
            NameFull: Bell, Melissa
      – PersonEntity:
          Name:
            NameFull: Irving, Adam
      – PersonEntity:
          Name:
            NameFull: Laramée, Philippe
      – PersonEntity:
          Name:
            NameFull: Irving, Adam H
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Text: Feb2016
              Type: published
              Y: 2016
          Identifiers:
            – Type: issn-print
              Value: 11727047
          Numbering:
            – Type: volume
              Value: 30
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: CNS Drugs
              Type: main
ResultId 1